Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI -Mel.A.) [ISRCTN75125874]
详细信息 查看全文
- 作者：Vanna Chiarion-Sileni (1)
Paola Del Bianco (2)
Antonella Romanini (3)
Michele Guida (4)
Adriano Paccagnella (5)
Maurizio Dalla Palma (6)
Emanuele Naglieri (4)
Ruggero Ridolfi (7)
Barbara Silvestri (8)
Maria Michiara (9)
Gian Luca De Salvo (2) - 刊名：BMC Cancer
- 出版年：2006
- 出版时间：December 2006
- 年：2006
- 卷：6
- 期：1
- 全文大小：933KB
- 参考文献：1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. / J Clin Oncol 2001, 19: 3622-634.
2. Jimenez RE, Panageas K, Busam KJ, Brady MS: Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma. / J Clin Oncol 2005, 23: 518-24. CrossRef
3. Lee ML, Tomsu K, Von Eschen KB: Duration of survival for disseminated malignant melanoma: results of a meta-analysis. / Melanoma Res 2000, 10: 81-2.
4. Moschos SJ, Edington HD, Rao UN, Jukic D, Shipe-Spotloe J, Land SR, Agarwala S, Kirkwood JM: High Dose Interferon-a2b (HDI): Toxicity, Response, and Predictive Markers in a Neoadjuvant trial for Regional Lymph Node Metastatic Melanoma. / Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings 2005, 23: 7517.
5. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. / J Clin Oncol 1996, 14: 7-7.
6. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. / J Clin Oncol 2001, 19: 1430-436.
7. Agarwala SS, Kirkwood JM: Update on adjuvant interferon therapy for high-risk melanoma. / Oncology (Huntingt) 2002, 16: 1177-7; discussion 1190-, 1197.
8. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E: Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. / J Clin Oncol 1996, 14: 2666-673.
9. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton AJ, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. / J Clin Oncol 2001, 19: 3635-648.
10. Hryniuk WM, Goodyear M: The calculation of received dose intensity. / J Clin Oncol 1990, 8: 1935-937.
11. Schuchter LM: Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? / J Clin Oncol 2004, 22: 7-0. CrossRef
12. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. / J Clin Oncol 2000, 18: 2444-458.
13. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. / J Clin Oncol 2001, 19: 2370-380.
14. Von Wussow P, Mohr P: Adjuvant intermittent high dose interferon-a-2b therapy in stage iic/iii malignant melanoma: A phase II study. / Proc Am Soc Clin Oncol 2003, 22: 724.
15. Watanabe N, Miura S, Yamaguchi E, Suzuki J, Kawakami Y: [A case of interferon-alpha-induced pneumonitis]. / Nihon Kyobu Shikkan Gakkai Zasshi 1993, 31: 1308-312.
16. Moriya K, Yasuda K, Koike K, Ichinose Y, Yotsuyanagi H, Kurokawa K, Iino S: Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. / J Gastroenterol 1994, 29: 514-17. CrossRef
17. Patel M, Ezzat W, Pauw KL, Lowsky R: Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. / Eur J Haematol 2001, 67: 318-21. CrossRef
18. Okanoue T, Sakamoto S, Yasui K, Takami S, Enjo F, Kashima K, Nakagawa Y, Tada H, Kanaoka H, Ohta M, / et al.: [Side effects of interferon on endocrine and respiratory system in 545 cases of chronic hepatitis C]. / Nippon Shokakibyo Gakkai Zasshi 1994, 91: 995-002.
19. Rocca P, Dumortier J, Taniere P, Duperret S, Vial T, Cottin V, Delafosse B, Scoazec JY, Boillot O: [Induced interstitial pneumonitis: role of pegylated interferon alpha 2b]. / Gastroenterol Clin Biol 2002, 26: 405-08.
20. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/44/prepub - 作者单位：Vanna Chiarion-Sileni (1)
Paola Del Bianco (2)
Antonella Romanini (3)
Michele Guida (4)
Adriano Paccagnella (5)
Maurizio Dalla Palma (6)
Emanuele Naglieri (4)
Ruggero Ridolfi (7)
Barbara Silvestri (8)
Maria Michiara (9)
Gian Luca De Salvo (2)
1. Department of Medical Oncology, University Hospital, Padua, Italy
2. Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto, Padua, Italy
3. Medical Oncology Unit, S. Chiara Hospital, Pisa, Italy
4. Medical Oncology Unit, Ospedale Oncologico, Bari, Italy
5. Medical Oncology Unit, SS Giovanni e Paolo Hospital, Venezia, Italy
6. Medical Oncology Unit, S. Bortolo Hospital, Vicenza, Italy
7. Oncology Dept, Pierantoni Hospital, Forlì, Italy
8. Medical Oncology Unit, General Hospital, Noale, Ve, Italy
9. Medical Oncology Unit, General Hospital, Parma, Italy - ISSN：1471-2407
文摘
Background High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the late nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without increasing the toxicity profile. The safety analysis in the first 169 patients who completed the treatment is here described. Methods Stage III melanoma patients were randomized to receive IFNalfa-2b 20 MU/m2/d intravenously (IV) 5 days/week × 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNalfa-2b 20 MU/m2/d IV 5 days/week × 4 weeks followed by 10 MU/m2 subcutaneously (SC) three times per week × 48 weeks (High Dose Interferon, HDI, arm). Toxicity was recorded and graded, according to the WHO criteria, as the worst grade that occurred during each cycle. Results The most common toxicities in both arms were flu-like and gastrointestinal symptoms, leukopenia, liver and neuro-psichiatric morbidities; with regard to severe toxicity, only leukopenia was statistically more frequent in DD/DI arm than in HDI arm (24% vs 9%) (p = 0.0074), yet, this did not cause an increase in the infection risk. Discontinuation of treatment, due to toxicity, was observed in 13 and 17% of the patients in the DD/DI and HDI arm, respectively. The median actual dose intensity delivered in the DD/DI arm (36.4 MU/m2/week) was statistically higher than that delivered in the HDI arm (30.7 MU/m2/week) (p = 0.003). Conclusion Four cycles of intravenous high-dose IFNalfa-2b can be safely delivered with an increase in the median dose intensity. Efficacy results from this trial are eagerly awaited.